- Vaccine Name: ChAd155-RG
- Target Pathogen: Rabies virus
- Target Disease: Rabies
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: RG vaccine antigen, RGN antigen, RNG vaccine antigens were inserted and evaluated in the CAd155 vector. (Napolitano et al., 2020)
- Preparation: One dose (1 ml (5x10^10 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel) (Napolitano et al., 2020)
- Immunization Route: Intramuscular injection (i.m.)
- Description: The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain. (Napolitano et al., 2020)
|
